创新药短线走弱，科创创新药ETF（589720）跌近2%，“924行情”以来跑赢主要港股创新药指数

Group 1 - The pharmaceutical sector is currently weakening, with the Kexin Innovation Drug ETF (GT) down nearly 2%, but there has been a net inflow of funds for two consecutive days as investors look for opportunities [1] - According to Guoyuan Securities, as the mid-year report season comes to an end, the market is shifting focus towards new directions, with optimism for innovative drugs, overseas expansion, and the clearing of centralized procurement in the second half of 2025 [1] - China's innovative drugs are entering a stage of realization, with significant research and development progress that is not affected by trade frictions, expected to remain a key investment theme in the pharmaceutical sector for 2025 [1] Group 2 - The Kexin Innovation Drug ETF (GT) focuses on innovative drug companies listed on the Sci-Tech Innovation Board, tracking an index of 30 representative high-quality companies, primarily in high-growth biotech, with a 20% limit on daily price fluctuations to better align with sector volatility [1] - From the performance perspective, since the "924 market," the Sci-Tech Innovation Drug Index has outperformed major Hong Kong innovative drug indices, with returns from September 24, 2024, to June 30, 2025, being 75% for the Sci-Tech Innovation Drug Index, compared to 70% for both the Hong Kong innovative drug index and the Hang Seng Hong Kong Stock Connect innovative drug index [1] - The Sci-Tech Innovation Drug Index may provide better exposure to the elasticity of the Sci-Tech Innovation Board when market risk appetite rebounds [1]